The trusted source for
healthcare information and
In a study cohort from the Alzheimer’s Disease Neuroimaging Initiative, cerebrospinal fluid levels of cholecystokinin were associated with better outcomes that may reflect compensatory protection as Alzheimer’s disease pathology progresses. However, because of significant study limitations, these findings need to be validated in additional studies.
Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Executive Editor Leslie Coplin; Editor Jonathan Springston; Editorial Group Manager Terrey L. Hatcher; and Accreditations Manager Amy M. Johnson, MSN, RN, CPN, report no financial relationships relevant to this field of study.